From: A comparative evaluation of medicine package inserts for oral antidiabetic agents in Palestine
Variable | Local Median [Q1-Q3] | Imported Median [Q1-Q3] | Mean rank for local products | Mean rank for imported products | P valuea | Fold difference in mean rank |
---|---|---|---|---|---|---|
Therapeutic class | 3.5 [1.5–4.5] | 8.0 [3.8–8.8] | 6.90 | 12.75 | 0.021 | 1.85 |
Indications | 21.8 [12.8–27.8] | 39.0 [26.3–48.8] | 6.90 | 12.75 | 0.021 | 1.84 |
Drug dose | 0.0 [0.0–13.5] | 43.0 [6.5–109.3] | 7.10 | 12.50 | 0.034 | 1.76 |
Missing dose | 38.5 [29.8–56.3] | 44.5 [19.8–88.5] | 9.35 | 9.69 | 0.897 | 1.04 |
Directions for use | 57.5 [25.8–77.8] | 58.5 [53.5–103.0] | 8.60 | 10.63 | 0.460 | 1.24 |
Overdose and management | 36 [35.5–48.3] | 104.0 [56.3–155.5] | 6.10 | 13.75 | 0.001 | 2.25 |
Warning and precautions | 36.5 [29.8–77.0] | 349.0 [302.3–441.3] | 5.50 | 14.50 | < 0.001 | 2.64 |
Effect on ability to drive and use machines | 0.0 [0.0–19.5] | 63.5 [42.0–77.8] | 6.70 | 13.00 | 0.012 | 1.94 |
Contraindications | 44.0 [29.5–59.3] | 128.0 [103.3–292.0] | 5.85 | 14.06 | < 0.001 | 2.40 |
Adverse drug reactions | 60.0 [36.3–128.5] | 367.5 [291.3–401.5] | 6.30 | 13.50 | 0.003 | 2.14 |
Drug-drug interactions | 56.0 [34.3–83.8] | 293.0 [108.5–467.5] | 6.10 | 13.75 | 0.001 | 2.25 |
Pregnancy considerations | 14.5 [9.3–23.8] | 29.5 [21.8–42.0] | 6.70 | 13.00 | 0.012 | 1.94 |
Lactation considerations | 10.0 [7.3–20.5] | 16.0 [13.3–25.0] | 7.75 | 11.69 | 0.122 | 1.51 |
Pediatric considerations | 6.5[0.0–14.5] | 10.0 [9.0–15.3] | 8.20 | 11.13 | 0.274 | 1.36 |
Possibility of tablet splitting | 0.0 [0.0–1.0] | 4.0 [0.75–5.8] | 7.10 | 12.50 | 0.034 | 1.76 |
Possibility of crushing and mixing with food or beverages | 0.0 [0.0–5.0] | 4.5 [1.0–5.0] | 8.30 | 11.00 | 0.315 | 1.33 |
Storage | 17.0 [16.5–23.3] | 101.5 [96.5–103.0] | 5.50 | 14.50 | < 0.001 | 2.64 |